Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Retained Earnings (2023 - 2025)

Compass Therapeutics' Retained Earnings history spans 3 years, with the latest figure at -$431.0 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 18.18% year-over-year to -$431.0 million; the TTM value through Dec 2025 reached -$431.0 million, down 18.18%, while the annual FY2025 figure was -$431.0 million, 18.18% down from the prior year.
  • Retained Earnings for Q4 2025 was -$431.0 million at Compass Therapeutics, down from -$415.5 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $486000.0 in Q3 2024 and bottomed at -$431.0 million in Q4 2025.
  • The 3-year median for Retained Earnings is -$296.9 million (2023), against an average of -$212.1 million.
  • The largest annual shift saw Retained Earnings tumbled 985729.73% in 2024 before it surged 311.11% in 2025.
  • A 3-year view of Retained Earnings shows it stood at $37000.0 in 2023, then crashed by 985729.73% to -$364.7 million in 2024, then fell by 18.18% to -$431.0 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Retained Earnings are -$431.0 million (Q4 2025), -$415.5 million (Q3 2025), and -$401.2 million (Q2 2025).